Fig. 7.

Celastrol protected against cisplatin-induced renal tubular cell apoptosis in vitro.

(a) Cell viability was analyzed by CCK8 assay after treatment with celastrol for 24 h at increasing concentrations ranging from 10 μM to 100 μM. Data were presented as means ± SD. ***P < 0.001 vs. vehicle group, n = 3 in each group. (b) Representative images of FACS analysis of Annexin V and PI staining. RTECs were pretreated with celastrol, and then incubated with cisplatin (5 μg/mL) for 24 h. (c) Percentage of apoptotic cells was determined by FACS. Data were presented as means ± SD. n = 3 in each group. (d) Western blots of Bax, Bcl-2 and cleaved caspase-3. (e) qRT-PCR analyses of renal Bax and Bcl-2 mRNA expressions. (f) qRT-PCR analyses of renal KIM-1 and NGAL mRNA expressions. GAPDH was used as internal control. All experiments were duplicated for three times. Statistically significant differences were determined by one-way ANOVA, ## P < 0.01, * P < 0.05, ** P < 0.01, ***P < 0.001.